OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
The importance of persistence in cancer drug development	1810
A new path to targeted protein degradation?	1728
A specific biomarker for insoluble tau	1100
Targeting tumour-associated bacteria	1069
The improving benefit–risk balance of phase I cancer trials	935
Neutralizing Zika virus	735
Upcoming market catalysts in Q3 2021	716
Vaccine exposes tumours to immune cell attack	673
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	638
Promoting tissue repair after heart attack	533
mRNA-encoded monoclonal antibody fights CHIKV	523
AI serves up target and inhibitor for lung fibrosis	474
FDA approves first all-oral sleeping sickness drug	470
Hypoimmune iPSCs escape immune detection	460
Anti-tau antibody stumbles in phase II Alzheimer trial	398
Glucose-sensitive insulin protects against hypoglycaemia	390
Tumour cells get a dendritic cell makeover	384
Degrading cell-free DNA to prevent recurrent stroke	381
FDA new drug approvals in Q1 2023	369
Apolipoprotein L2 inhibitor mitigates fibrosis	360
Lipid nanoparticle ferries therapeutic mRNA to the placenta	356
New antibiotic for urinary tract infections nabs FDA approval	354
FDA approves second TTR stabilizer for cardiac amyloidosis	353
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	352
Targeting drug-resistant glioblastoma	349

First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	342
Evolution of innovative drug R&D in China	327
Top companies and drugs by sales in 2021	323
2022 FDA approvals	311
Chemical engineering of CRISPR–Cas systems for therapeutic application	265
Small-molecule discovery through DNA-encoded libraries	262
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	254
mRNA vaccines for infectious diseases — advances, challenges and opportunities	246
Increasing the potency of T cell therapies	240
Pushing both sides of the drug pricing aisle	238
Predicting Alzheimer disease dementia	235
Reflections on 10 years of the FDA’s breakthrough therapy designation	232
Blocking breast cancer metastasis	229
Rewired proteostasis in KRAS inhibitor resistance	216
Small molecule improves muscle function in myasthenia gravis	208
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	198
R&D re-balancing act	195
Host-directed antiviral blocks SARS-CoV-2 entry	186
Inhibiting ASGR1 boosts cholesterol removal	184
The significance of blockbusters in the pharmaceutical industry	178
Base editors hit the clinic	174
Combating antimicrobial resistance in malaria, HIV and tuberculosis	173
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	167
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	149
TCR-engineered T cells get personal	148
Screening ultra-large virtual libraries	147
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	146
A call to action for translational sciences in COVID-19 and future pandemics	144
FDA approves second BCMA-targeted CAR-T cell therapy	141
FDA new drug approvals in Q2 2023	141
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	139
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	138
The antibody–drug conjugate landscape	136
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials	135
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	134
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	131
Phenotypic drug discovery: recent successes, lessons learned and new directions	125
The emerging role of mass spectrometry-based proteomics in drug discovery	122
Pan-coronavirus vaccine pipeline takes form	115
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	110
Antibody–drug conjugates come of age in oncology	106
Ribosome inhibitor combats bacterial drug resistance	105
Reducing IL-2 toxicity	100
A novel single-agent antibiotic	100
Gut metabolite mediates nerve repair	100
Agonist antibody lowers blood pressure	100
Immunology on the brain	98
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	94
Multi-TACs target solid tumours	94
What does AlphaFold mean for drug discovery?	92

The malignant melanoma market	91
Neglected tropical diseases go global	89
Monkeypox mRNA vaccine protects mice and macaques	88
The European Innovation Network as a hub for medicines innovation in Europe	87
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	85
Anti-IL-11 antibody shows anti-ageing properties	85
Author Correction: PI3K inhibitors are finally coming of age	84
LRRK2-targeted Parkinson disease drug advances into phase III	83
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	83